Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a...
Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen
Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its in-house developed isophane protamine recombinant...
Hansoh Pharma’s B7-H3 ADC HS-20093 Secures Fourth NMPA Breakthrough Therapy Designation for NSCLC Combination Therapy
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) has announced that its investigational antibody-drug conjugate (ADC),...
Hengrui Pharma’s Nectin-4 ADC SHR-A2102 Granted Second NMPA Breakthrough Therapy Designation for Cervical Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 therapeutic...
Abbott Reports 3.8% YOY Revenue Growth in Q1 2026, Led by Diagnostics and Medical Devices
Abbott Laboratories (NYSE: ABT) announced its financial results for the first quarter of 2026, reporting...
Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials
Tigermed Consulting Co., Ltd. (SHE: 300347), a leading Chinese Contract Research Organization (CRO), has announced...
Amoytop Biotech Inks $445M Deal with Aligos for China Rights to Novel Hepatitis B Capsid Modulator Pevifoscorvir
Amoytop Biotech Co., Ltd. (SHA: 688278), a leading Chinese biopharmaceutical company, has entered into a...
Changchun High & New Tech Gains NMPA Clearance for GenSci136 Phase I/II Trial in Generalized Myasthenia Gravis
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a major Chinese biopharmaceutical company,...
Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy’s Molteni Farmaceutici
Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new...
GE HealthCare and DeepHealth Expand Global Partnership to Advance AI-Powered Mammography Solutions
GE HealthCare Technologies Inc. (NASDAQ: GEHC), a global leader in medical technology and life sciences,...
Betta Pharmaceuticals Partners with Eversana for US Commercialization of Ensartinib in ALK+ NSCLC
Betta Pharmaceuticals Co., Ltd. (SHE: 300558), a China-based oncology-focused biopharma company, has entered into a...
Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio
Kailera Therapeutics, Inc. (NASDAQ: KLRA), a US-based biotech venture established in 2024 by China’s Jiangsu...
WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients
Hong Kong WinHealth Pharma Group announced that China’s National Medical Products Administration (NMPA) has granted...
RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal
RemeGen Ltd (HKG: 9995) has announced the receipt of USD 650 million in upfront payment...
Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth
Annoroad Gene Technology (Beijing) Co., Ltd. has filed a prospectus with the Hong Kong Stock...
Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has announced that China’s National Medical...
Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration
Gan & Lee Pharmaceuticals (SHA: 603087) has announced that China’s National Medical Products Administration (NMPA)...
Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer
Sino Biopharmaceutical Ltd (HKG: 1177) has announced the enrollment of the first patient in a...
Mabwell Bioscience Secures Second NMPA Approval for Denosu, China’s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China’s...
CSPC Pharmaceutical Secures NMPA Clinical Trial Approval for SYS6051, a Tissue Factor-Targeted ADC for Advanced Solid Tumors
CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that China’s National Medical Products Administration (NMPA)...